CUROSURF is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants.

CUROSURF reduces mortality and pneumothoraces associated with RDS.

---

Respiratory Distress Syndrome -- A group of conditions characterized by failure of normal respiration caused by lack of lung surfactant.

Pneumothorax -- An accumulation of air or gas in the pleural space, which may occur spontaneously or as a result of trauma or a pathological process, or be introduced deliberately ( = PNEUMOTHORAX, ARTIFICIAL). (Dorland, 27th ed)

CUROSURF is intended for intratracheal use only.THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE.

Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of pre-term infants.TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION.

These events require stopping Curosurf administration and taking appropriate measures to alleviate the condition.

After the patient is stable, dosing may proceed with appropriate monitoring.